MK-0518 Isentress Raltegravir Potassium MK0518 POTASSIUM Raltegravir monopotassium salt BDBM50480673 Isentress hd MK-0518 POTASSIUM
BDBM25351 N-[2-(4-{[(4-fluorophenyl)methyl]carbamoyl}-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl)propan-2-yl]-5-methyl-1,3,4-oxadiazole-2-carboxamide Raltegravir
- Summa, V; Petrocchi, A; Bonelli, F; Crescenzi, B; Donghi, M; Ferrara, M; Fiore, F; Gardelli, C; Gonzalez Paz, O; Hazuda, DJ; Jones, P; Kinzel, O; Laufer, R; Monteagudo, E; Muraglia, E; Nizi, E; Orvieto, F; Pace, P; Pescatore, G; Scarpelli, R; Stillmock, K; Witmer, MV; Rowley, M Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 51: 5843-55 (2008)
- Zhao, XZ; Smith, SJ; Métifiot, M; Marchand, C; Boyer, PL; Pommier, Y; Hughes, SH; Burke, TR 4-amino-1-hydroxy-2-oxo-1,8-naphthyridine-containing compounds having high potency against raltegravir-resistant integrase mutants of HIV-1. J Med Chem 57: 5190-202 (2014)
- Zhao, XZ; Smith, SJ; Métifiot, M; Johnson, BC; Marchand, C; Pommier, Y; Hughes, SH; Burke, TR Bicyclic 1-hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-containing HIV-1 integrase inhibitors having high antiviral potency against cells harboring raltegravir-resistant integrase mutants. J Med Chem 57: 1573-82 (2014)